9th NovAliX Conference | Hybrid Event

Biophysics in Drug Discovery 2023 | US Edition

Developing the Synergy between Biophysics and Medicinal Chemistry to Deliver Better Drugs

 Philadelphia, PA, United States & Virtual    April 26-28, 2023

Keynote Speakers

Sequence Based Design of RNA Targeted Small Molecules

Prof. Matthew DISNEY
UF SCRIPPS, Jupiter, United States
Read more

Reimagining Druggability using Chemoproteomic Platforms

Prof. Daniel NOMURA
UC BERKELEY, Berkeley, United States
Read more

How Biophysics can Advance a Small Molecule Neuroscience Portfolio

Dr Laura SILVIAN
BIOGEN, Cambridge, United States
Read more

Session 1: Emerging Technologies - New Biophysical Approaches for Measuring Molecular Interactions

Title of talk to be announced (virtual presentation)

Dr Jonathan BROOKS
PFIZER, Cambridge, United States

Title of talk to be announced

Dr Pedro SERRANO NAVARRO
TAKEDA CALIFORNIA, INC., San Diego, United States

Session 2: Covalent Drug Discovery

In-cell Covalent Inhibitors Discovery

Dr Brent MARTIN
SCORPION THERAPEUTICS, Boston, United States
Read more

Developing Covalent Small Molecules for the Protein Targets from Kinase to Transcription Factor

Dr Tinghu ZHANG
STANFORD, Stanford, United States
Read more

Session 3: Hybrid Methods and Technique Combinations

Integration of Biophysics and Simulation to Drive Drug Discovery

Dr Holly SOUTTER
BROAD INSTITUTE, Cambridge, United States
Read more

Session 4: Biophysical Assays for PROTACs and Molecular Glues

Structural and Biophysical Studies of Protein Degrader Ternary Complexes

Dr Matthew CALABRESE
PFIZER, Groton, United States
Read more

An Integrated Biophysical Approach to Discover Ligands for a Novel E3 Ligase

Dr Nichole O'CONNELL
KYMERA THERAPEUTICS, Watertown, United States
Read more

Session 5: Small Molecules Targeting RNA / Understanding Small-Molecule Selectivity Towards RNA

Title of talk to be announced

Dr Elena MENICHELLI
ARRAKIS THERAPEUTICS, Waltham, United States

Exploring the Undiscovered Country of RNA as a Drug target—Finding Bioactive Ligands against XIST RNA with Affinity-selection MS Screening

Dr Elliott B. NICKBARG
MERCK RESEARCH LABORATORIES, Boston, United States
Read more